Search results
Home Phototherapy for Psoriasis: Optimizing Access
Medscape· 4 days agoSupporters of home phototherapy for patients with plaque and guttate psoriasis had plenty to cheer about at the annual meeting of the American Academy of...
Zai Lab doses first subject in Phase II plaque psoriasis treatment trial
Clinical Trials Arena via Yahoo Finance· 3 days agoThe randomised, global, double-blind, vehicle-controlled, dose-ranging trial is designed to assess...
Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief
Verywell Health via Yahoo News· 5 days agoMy arms were cherry red due to...in 2010, but knowing I wanted more babies deterred me from seeking ...
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 5 days agoJ&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 6 days ago“We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey...
State board targets six prescription drugs to review for affordability for Marylanders
Maryland Matters via Yahoo News· 6 days agoThe board will seek public comments, additional information and data over the next 60 days to...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
WPRI Providence· 3 days agoIn these studies, bimekizumab consistently demonstrated sustained improvements in clinical...
Ultravate side effects: What they are and how to manage them
Healthline· 6 days agoUltravate (halobetasol propionate) is a prescription drug that’s used to treat plaque psoriasis. Ultravate can cause side effects that range from mild to ...
AbbVie (NYSE:ABBV) vs. Cosmo Pharmaceuticals (OTC:CMOPF) Head to Head Review
ETF DAILY NEWS· 2 days agoAbbVie (NYSE:ABBV – Get Free Report) and Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses ...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 6 days ago...20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative colitisa (UC) receiving subcutaneous (SC) TREMFYA® (guselkumab) 200 mg...